A placebo-controlled trial of memantine as an adjunct to injectable extended-release naltrexone for opioid dependence

Journal of Substance Abuse Treatment

Volumn 46, Issue 5, 2014, Pages 546-552

  Bisaga, Adam ^a   Sullivan, Maria A ^a   Glass, Andrew ^a   Mishlen, Kaitlyn ^a   Carpenter, Kenneth M ^a   Mariani, John J ^a   Levin, Frances R ^a   Nunes, Edward V ^a  

^a Department of Psychiatry Columbia University College of Physicians and Surgeons ^*  (United States)

Author keywords

Memantine; Naltrexone; NMDA receptors; Opiate dependence; Pharmacotherapy trials

Indexed keywords

MEMANTINE; NALTREXONE; PLACEBO; AMINO ACID RECEPTOR BLOCKING AGENT; DELAYED RELEASE FORMULATION; NARCOTIC ANTAGONIST;

ADULT; ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG RELEASE; EXTENDED DRUG RELEASE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OPIATE ADDICTION; PRIORITY JOURNAL; RELAPSE; TREATMENT DURATION; WITHDRAWAL SYNDROME; YOUNG ADULT; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; CONTROLLED STUDY; DELAYED RELEASE FORMULATION; DOUBLE BLIND PROCEDURE; OPIOID-RELATED DISORDERS; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; SUBSTANCE WITHDRAWAL SYNDROME;

ADULT; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; HUMANS; MALE; MEMANTINE; MIDDLE AGED; NALTREXONE; NARCOTIC ANTAGONISTS; OPIOID-RELATED DISORDERS; RECURRENCE; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 84897060390     PISSN: 07405472     EISSN: 18736483     Source Type: Journal    
DOI: 10.1016/j.jsat.2014.01.005     Document Type: Article

References (22)

1. Bisaga A., Comer S.D., Ward A.S., Popik P., Kleber H.D., Fischman M.W. The NMDA antagonist memantine attenuates the expression of opioid physical dependence in humans. Psychopharmacology 2001, 157:1-10.
2. Bisaga A., Sullivan M.A., Cheng W.Y., Carpenter K.M., Mariani J.J., Levin F.R., et al. A placebo controlled trial of memantine as an adjunct to oral naltrexone for opioid dependence. Drug and Alcohol Dependence 2011, 119:e23-e29.
3. CASA Columbia T. Addiction medicine: Closing the gap between science and practice 2012, The National Center on Addiction and Substance Abuse at Columbia University, New York.
4. CDC CDC grand rounds: prescription drug overdoses - a U.S. epidemic. MMWR. Morbidity and Mortality Weekly Report 2012, 61:10-13.
5. Comer S.D., Sullivan M.A. Memantine produces modest reductions in heroin-induced subjective responses in human research volunteers. Psychopharmacology 2007, 193:235-245.
6. Comer S.D., Sullivan M.A., Hulse G.K. Sustained-release naltrexone: Novel treatment for opioid dependence. Expert Opinion on Investigational Drugs 2007, 16:1285-1294.
7. First M.B., Spitzer R.L., Gibbon M., Williams J.B.W. Structured Clinical Interview for DSM-IV Axis I disorders - patient edition (SCID-I/P, Version 2.0) 1995, Biometrics Research Department, New York State Psychiatric Institute, New York, NY.
8. Foster J., Brewer C., Steele T. Naltrexone implants can completely prevent early (1-month) relapse after opiate detoxification: A pilot study of two cohorts totalling 101 patients with a note on naltrexone blood levels. Addiction Biology 2003, 8:211-217.
9. Haney M. Self-administration of cocaine, cannabis and heroin in the human laboratory: Benefits and pitfalls. Addiction Biology 2009, 14:9-21.
10. Harris A.C., Rothwell P.E., Gewirtz J.C. Effects of the NMDA receptor antagonist memantine on the expression and development of acute opiate dependence as assessed by withdrawal-potentiated startle and hyperalgesia. Psychopharmacology 2008, 196:649-660. 10.1007/s00213-007-0998-2.
11. Hulse G.K., Morris N., Arnold-Reed D., Tait R.J. Improving clinical outcomes in treating heroin dependence: Randomized, controlled trial of oral or implant naltrexone. Archives of General Psychiatry 2009, 66:1108-1115. 10.1001/archgenpsychiatry.2009.130.
12. Krupitsky E., Masalov D.V., Burakov A.M., Didenko T.Y., Romanova T.N., Bespalov Y., et al. A pilot sudy of memantine effects on protracted withdrawal (syndrome of anhedonia) in heroin addicts. Addictive Disorders & Their Treatment 2002, 1:143-146.
13. Krupitsky E., Zvartau E., Blokhina E., Verbitskaya E., Wahlgren V., Tsoy-Podosenin M., et al. Randomized trial of long-acting sustained-release naltrexone implant vs oral naltrexone or placebo for preventing relapse to opioid dependence. Archives of General Psychiatry 2012, 69:973-981. 10.1001/archgenpsychiatry.2012.1a.
14. Mattick R.P., Kimber J., Breen C., Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane database of systematic reviews 2008, CD002207.
15. Popik P., Skolnick P. The NMDA antagonist memantine blocks the expression and maintenance of morphine dependence. Pharmacology, Biochemistry and Behavior 1996, 53:791-797.
16. Popik P., Wrobel M., Bisaga A. Reinstatement of morphine-conditioned reward is blocked by memantine. Neuropsychopharmacology 2006, 31:160-170.
17. Rothenberg J.L., Sullivan M.A., Church S.H., Seracini A., Collins E., Kleber H.D., et al. Behavioral naltrexone therapy: An integrated treatment for opiate dependence. Journal of Substance Abuse Treatment 2002, 23:351-360.
18. SAMHSA An introduction to extended-release injectable naltrexone for the treatment of people with opioid dependence. SAMHSA Advisory 2012, S. A. a. M. H. S. Administration (Ed.).
19. SAMHSA Results from the 2012 National Survey on Drug Use and Health: Summary of national findings 2013, Substance Abuse and Mental Health Services Administration, Rockville, MD.
20. Sigmon S.C., Bisaga A., Nunes E.V., O'Connor P.G., Kosten T., Woody G. Opioid detoxification and naltrexone induction strategies: Recommendations for clinical practice. American journal of drug and alcohol abuse 2012, 38:187-199.
21. Sullivan M.A., Bisaga A., Mariani J.J., Glass A., Levin F.R., Comer S.D., et al. Naltrexone treatment for opioid dependence: Does its effectiveness depend on testing the blockade?. Drug and Alcohol Dependence 2013, 10.1016/j.drugalcdep.2013.05.030.
22. Sullivan M.A., Rothenberg J.L., Vosburg S.K., Church S.H., Feldman S.J., Epstein E.M., et al. Predictors of retention in naltrexone maintenance for opioid dependence: Analysis of a stage I trial. American journal on addictions 2006, 15:150-159.